Abbonarsi

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS): Rationale and design of a cluster-randomized trial - 26/11/20

Doi : 10.1016/j.ahj.2020.08.009 
Katherine T. Mills, PhD a, c, Erin Peacock, PhD b, Jing Chen, MD, MSc a, b, c, Amanda Zimmerman, MPH a, Kenya Brooks, MPH a, Hua He, PhD a, c, Alecia Cyprian, PhD d, Gerrelda Davis, MBA e, Sonja R. Fuqua, PhD, RN f, Angelique Greer, MPH g, Lea Gray-Winfrey, DNP, APRN h, Shondra Williams, PhD, APRN i, Gary M. Wiltz, MD j, Keith L. Winfrey, MD, MPH k, Paul K. Whelton, MD, MSc a, b, c, Marie Krousel-Wood, MD, MSPH a, b, c, Jiang He, MD, PhD a, b, c, ⁎
a Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 
b Department of Medicine, Tulane University School of Medicine, New Orleans, LA 
c Tulane University Translational Sciences Institute, New Orleans, LA 
d Southeast Community Health Systems, Greensburg, LA 
e Louisiana Primary Care Association, Baton Rouge, LA 
f Community Health Center Association of Mississippi, Jackson, MS 
g Coastal Family Health Center, Biloxi, MS 
h EXCELth, Inc., New Orleans, LA 
i InclusivCare, Avondale, LA 
j Teche Action Board, Inc., Franklin, LA 
k NOELA Community Health Center, New Orleans, LA 

⁎Reprint requests: Jiang He, MD, PhD, Tulane University School of Public Health and Tropical Medicine, 1440 Canal St, Suite 2000, New Orleans, LA 70112Tulane University School of Public Health and Tropical Medicine1440 Canal St, Suite 2000New OrleansLA70112

Abstract

Background

The Systolic Blood Pressure Intervention Trial (SPRINT) reported that intensive blood pressure (BP) treatment reduced cardiovascular disease and mortality compared to standard BP treatment in hypertension patients. The next important question is how to implement more intensive BP treatment in real-world clinical practice. We designed an effectiveness-implementation hybrid trial to simultaneously test the effectiveness of a multifaceted intervention for intensive BP treatment and its feasibility, fidelity, and sustainability in underserved hypertension patients.

Methods

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS) is a cluster randomized trial conducted in 36 Federally Qualified Health Center clinics in Louisiana and Mississippi. Federally Qualified Health Center clinics were randomized to either a multifaceted intervention for intensive BP treatment, including protocol-based treatment using the SPRINT intensive BP management algorithm, dissemination of SPRINT findings, BP audit and feedback, home BP monitoring, and health coaching, or enhanced usual care. Difference in mean systolic BP change from baseline to 18 months is the primary clinical effectiveness outcome, and intervention fidelity, measured by treatment intensification and medication adherence, is the primary implementation outcome. The planned sample size of 1,260 participants (36 clinics with 35 participants each) has 90% power to detect a 5.0–mm Hg difference in systolic BP at a .05 significance level and 80% follow-up rate.

Conclusions

IMPACTS will generate critical data on the effectiveness and implementation of a multifaceted intervention for intensive BP treatment in real-world clinical practice and could directly impact the BP-related disease burden in minority and low-income populations in the United States.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


☆ Declarations of interest: None.
☆☆ Trial registration: Clinicaltrials.gov number NCT03483662.


© 2020  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 230

P. 13-24 - dicembre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Cardiac safety research consortium “shock II” think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock
  • Marc D. Samsky, Mitchell W. Krucoff, David A. Morrow, William T. Abraham, Fernando Aguel, Andrew D. Althouse, Eric Chen, Joaquin E. Cigarroa, Adam D. DeVore, Andrew Farb, Ian C. Gilchrist, Timothy D. Henry, Judith S. Hochman, Navin K. Kapur, Valarie Morrow, E. Magnus Ohman, William W. O'Neill, Ileana L Piña, Alastair G. Proudfoot, John S. Sapirstein, Jonathan H. Seltzer, Fred Senatore, Meir Shinnar, Charles A. Simonton, Behnam N. Tehrani, Holger Thiele, Alexander G. Truesdell, Ron Waksman, Sunil V. Rao
| Articolo seguente Articolo seguente
  • Effect of permanent right internal mammary artery occlusion on right coronary artery supply: A randomized placebo-controlled clinical trial
  • Marius R. Bigler, Michael Stoller, Christine Tschannen, Raphael Grossenbacher, Christian Seiler

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.